197 lines
44 KiB
Text
197 lines
44 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK501534">
|
|
<meta name="ncbi_domain" content="lactmed">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK501534/?report=reader">
|
|
<meta name="ncbi_pagename" content="Efavirenz - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Efavirenz - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/lactmed/LM1194/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/lactmed/efgartigimod_alfa/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/lactmed/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="Drugs and Lactation Database (LactMed®) [Internet]">
|
|
<meta name="citation_title" content="Efavirenz">
|
|
<meta name="citation_publisher" content="National Institute of Child Health and Human Development">
|
|
<meta name="citation_date" content="2024/07/15">
|
|
<meta name="citation_pmid" content="30000594">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK501534/">
|
|
<meta name="citation_keywords" content="Efavirenz">
|
|
<meta name="citation_keywords" content="Sustiva">
|
|
<meta name="citation_keywords" content="Atripla">
|
|
<meta name="citation_keywords" content="Symfi">
|
|
<meta name="citation_keywords" content="EFV">
|
|
<meta name="citation_keywords" content="HSDB 7163">
|
|
<meta name="citation_keywords" content="L 743726">
|
|
<meta name="citation_keywords" content="Stocrin">
|
|
<meta name="citation_keywords" content="DMP 266">
|
|
<meta name="citation_keywords" content="DMP-266">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Efavirenz">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Child Health and Human Development">
|
|
<meta name="DC.Date" content="2024/07/15">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK501534/">
|
|
<meta name="description" content="Efavirenz is excreted into breastmilk and small amounts are found in the serum of some infants. Treatment of mothers of HIV-positive mothers with efavirenz does not appear to affect growth and development of their HIV-negative breastfed infants. Achieving and maintaining viral suppression with antiretroviral therapy decreases breastfeeding transmission risk to less than 1%, but not zero. Individuals with HIV who are on antiretroviral therapy with a sustained undetectable viral load and who choose to breastfeed should be supported in this decision. If a viral load is not suppressed, banked pasteurized donor milk or formula is recommended.[1,2]">
|
|
<meta name="og:title" content="Efavirenz">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Efavirenz is excreted into breastmilk and small amounts are found in the serum of some infants. Treatment of mothers of HIV-positive mothers with efavirenz does not appear to affect growth and development of their HIV-negative breastfed infants. Achieving and maintaining viral suppression with antiretroviral therapy decreases breastfeeding transmission risk to less than 1%, but not zero. Individuals with HIV who are on antiretroviral therapy with a sustained undetectable viral load and who choose to breastfeed should be supported in this decision. If a viral load is not suppressed, banked pasteurized donor milk or formula is recommended.[1,2]">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK501534/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-lactmed-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/lactmed/LM644/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK501534/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8E3CCB7D813BF1000000000134010D.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK501534/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/lactmed/LM1194/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Efavirenz</div><div class="j">Drugs and Lactation Database (LactMed®) [Internet]</div></div><div class="tail"><a href="/books/n/lactmed/efgartigimod_alfa/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK501534/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK501534/&text=Efavirenz"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/lactmed/?report=reader">Title Information</a><a href="/books/n/lactmed/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK501534/?report=classic">Switch to classic view</a><a href="/books/NBK501534/pdf/Bookshelf_NBK501534.pdf">PDF (130K)</a><a href="/books/NBK501534/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK501534%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8E3CCB7D813BF1000000000134010D.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK501534_"><span class="title" itemprop="name">Efavirenz</span></h1><p class="fm-aai"><a href="#_NBK501534_pubdet_">Publication Details</a></p><p><em>Estimated reading time: 8 minutes</em></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><p>CASRN: 154635-17-3</p><a href="https://pubchem.ncbi.nlm.nih.gov/substance/389072779" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=389072779" alt="image 389072779 in the ncbi pubchem database" /></a><div id="LM644.Drug_Levels_and_Effects"><h2 id="_LM644_Drug_Levels_and_Effects_">Drug Levels and Effects</h2><div id="LM644.Summary_of_Use_during_Lactation"><h3>Summary of Use during Lactation</h3><p>Efavirenz is excreted into breastmilk and small amounts are found in the serum of some infants. Treatment of mothers of HIV-positive mothers with efavirenz does not appear to affect growth and development of their HIV-negative breastfed infants. Achieving and maintaining viral suppression with antiretroviral therapy decreases breastfeeding transmission risk to less than 1%, but not zero. Individuals with HIV who are on antiretroviral therapy with a sustained undetectable viral load and who choose to breastfeed should be supported in this decision. If a viral load is not suppressed, banked pasteurized donor milk or formula is recommended.[<a class="bibr" href="#LM644.REF.1" rid="LM644.REF.1">1</a>,<a class="bibr" href="#LM644.REF.2" rid="LM644.REF.2">2</a>]</p></div><div id="LM644.Drug_Levels"><h3>Drug Levels</h3><p><i>Maternal Levels.</i> Thirteen mothers who averaged 15.8 weeks (range 6 to 25 weeks) postpartum were treated with efavirenz 600 mg daily plus zidovudine and lamivudine. Milk and plasma samples were taken 3 to 4 hours after the last dose. Skimmed breastmilk efavirenz concentrations averaged 3.5 mg/L (range 1.3 to 7.4 mg/L).[<a class="bibr" href="#LM644.REF.3" rid="LM644.REF.3">3</a>]</p><p>Five mothers who were taking oral efavirenz 600 mg daily as part of an antiretroviral regimen collected mid-feed milk samples at 0.5, 1, 2, 4, 8, 12 and 24 hours after an evening dose at an average of 146 days after delivery. The average peak level of 4.5 mg/L occurred at about 4 hours after the dose and the average trough milk value was 2.5 mg/L.[<a class="bibr" href="#LM644.REF.4" rid="LM644.REF.4">4</a>]</p><p>One hundred thirty-four mothers who were taking efavirenz 600 mg at bedtime as part of their antiretroviral regimen and their infants were studied. In the first part of the study, women were separated into noncarriers, homozygotes and homozygotes for the CYP2B6 516TT gene. Random breastmilk concentrations had median values of 1610, 2370 and 4070 mcg/L in the three groups, respectively. A pooled subset of 29 mothers underwent extensive sampling of plasma and breastmilk sampling, encompassing 203 paired maternal plasma and breastmilk levels. In these mothers the median peak breastmilk levels were 4020 4540 and 8920 mcg/L, respectively. Corresponding trough milk levels were 1120, 1500, and 2480 mcg/L. The authors estimated that the average dosages that infants would receive would be 344 mcg/kg, 379 mcg/kg and 1340 mcg/kg daily in the maternal noncarrier, heterozygous and homozygous groups, respectively.[<a class="bibr" href="#LM644.REF.5" rid="LM644.REF.5">5</a>] A physiologically based pharmacokinetic model was created by the authors and compared to the 29 pooled patients’ data. Over 80% of observed data points were within the model’s predictive interval.[<a class="bibr" href="#LM644.REF.6" rid="LM644.REF.6">6</a>] Another model based on data from this study found that the simulated average milk concentrations were 2.31 mg/L, 2.89 mg/L and 4.63 mg/L from CYP2B6 516GG, GT, and TT mothers, respectively. These translated to average daily infant dosages of 0.35, 0.43, and 0.69 mg/kg, respectively.[<a class="bibr" href="#LM644.REF.7" rid="LM644.REF.7">7</a>]</p><p>Women in Malawi received the option B+ regimen for prevention of mother-to-child transmission of HIV consisting of tenofovir, lamivudine and efavirenz between 6 and 8 pm daily. The efavirenz dose was not stated, but was presumably 600 mg daily. Milk samples collected in the morning from 33 women at month 1 postpartum had a median efavirenz concentration of 1.6 mg/L (IQR 0.86 to 2.3 mg/L). Milk samples collected in the morning from 47 women at month 12 postpartum had a median efavirenz concentration of 1.8 mg/L (IQR 1.0 to 4.3 mg/L).[<a class="bibr" href="#LM644.REF.8" rid="LM644.REF.8">8</a>]</p><p>Mother-infant pairs were studied among mothers taking efavirenz 600 mg daily as part of a multi-drug HIV regimen. Mothers hand-express milk samples 12 to 14 hours after a morning dose at 1, 3 and 6 months postpartum. Median breastmilk efavirenz concentrations at 1, 3, and 6 months were 4.66 mg/L (n = 22) , 4.16 mg/L (n = 31) and 3.92 mg/L (n = 30), respectively. The weight-adjusted infant dosage was calculated to be 2.46% at 6 months.[<a class="bibr" href="#LM644.REF.9" rid="LM644.REF.9">9</a>]</p><p>Three mothers taking efavirenz 600 mg once daily provided milk samples at a median of 18 hours after a dose. The median drug concentration in milk was 2701 mcg/L, which resulted in an estimated infant dosage of 0.41 mg/kg daily and a relative infant dose of 1.35% of the maternal weight-adjusted dosage.[<a class="bibr" href="#LM644.REF.10" rid="LM644.REF.10">10</a>]</p><p><i>Infant Levels.</i> Thirteen mothers who averaged 15.8 weeks (range 6 to 25 weeks) postpartum were treated with efavirenz 600 mg daily plus lamivudine and zidovudine (n = 12) or stavudine (n = 1). Plasma samples were taken from their breastfed infants 3 to 4 hours after the last dose. Infant plasma concentrations averaged 0.86 mg/L (range 0.4 to 1.5 mg/L). Infant plasma concentrations averaged 13% of maternal plasma concentrations, but there was no statistically significant correlation between them. Average plasma levels were slightly below the plasma level considered effective for suppression of HIV in adults.[<a class="bibr" href="#LM644.REF.3" rid="LM644.REF.3">3</a>]</p><p>Efavirenz was measured in 117 breastfed (90% exclusive) infants whose mothers were taking efavirenz for HIV infection during pregnancy and postpartum. All infants had detectable efavirenz in their plasma samples at 0 (mean 1.7 mg/L), 8 (mean 0.3 mg/L) and 12 (mean 0.3 mg/L) weeks postpartum. All infants had detectable efavirenz in their hair samples at 12 weeks postpartum at a mean concentration of 1.9 mcg/gram of hair (range 0.34 to 11 mcg/gram). The authors interpreted the results to mean that infants receive substantial exposure to efavirenz during breastfeeding.[<a class="bibr" href="#LM644.REF.11" rid="LM644.REF.11">11</a>]</p><p>One hundred thirty-four mothers who were taking efavirenz 600 mg at bedtime as part of their antiretroviral regimen and their infants were studied. In the first part of the study, women were separated into noncarriers, homozygotes and homozygotes for the CYP2B6 516TT gene. Random infant serum concentrations had median values of 124, 164, and 333 mcg/L in the three groups, respectively. A subset of mothers and infants underwent extensive sampling of plasma and breastmilk sampling. In these infants, median plasma levels were 166, 89 and 293 mcg/L at 2 hours after the maternal dose and 134, 86 and 342 mcg/L at 8 hours after the maternal dose, respectively.[<a class="bibr" href="#LM644.REF.5" rid="LM644.REF.5">5</a>]</p><p>Blood samples were taken from 25 breastfed infants of mothers who were receiving option B+ regimen for prevention of mother-to-child transmission of HIV consisting of tenofovir, lamivudine and efavirenz between 6 and 8 pm daily. The efavirenz dose was not stated, but was presumably 600 mg daily. The median morning infant plasma concentration of efavirenz at 6 months of age was 86.4 mcg/L (IQR 0 to 329 mcg/L). The median morning infant plasma concentration of efavirenz at 12 months of age was 0 mcg/L.[<a class="bibr" href="#LM644.REF.8" rid="LM644.REF.8">8</a>]</p><p>Mother-infant pairs were studied among mothers taking efavirenz 600 mg daily as part of a multi-drug HIV regimen. Infants were breastfed (extent not stated) and plasma concentrations were measured postpartum. Median plasma efavirenz concentrations at 1, 3, and 6 months were 347 mcg/L (n = 22), 268 mcg/L (n = 30), and 175 mcg/L (n = 17), respectively. These plasma concentrations ranged from 4.8% to 7.2% of simultaneous maternal plasma levels.[<a class="bibr" href="#LM644.REF.9" rid="LM644.REF.9">9</a>]</p><p>An infant was breastfed by a mother taking efavirenz 600 mg once daily, although the extent of breastfeeding was not sated. The infant’s serum concentrations taken 17 hours after maternal drug intake at 1 month of age was 267 mcg/L.[<a class="bibr" href="#LM644.REF.10" rid="LM644.REF.10">10</a>]</p></div><div id="LM644.Effects_in_Breastfed_Infants"><h3>Effects in Breastfed Infants</h3><p>Thirteen mothers nursed their infants while they were taking efavirenz 600 mg daily, lamivudine 150 mg and zidovudine 300 mg daily (n = 12) or stavudine 60 mg daily (n = 1) . No adverse reactions were reported in the infants after 6 months of breastfeeding, none had developed HIV infection and all were developing normally.[<a class="bibr" href="#LM644.REF.3" rid="LM644.REF.3">3</a>]</p><p>An unblinded study in Uganda compared the outcomes of breastfed infants and their HIV-positive mothers who were randomized to receive antiretroviral therapy that was based either on efavirenz 600 mg once daily or lopinavir 400 mg plus ritonavir 100 mg twice daily during breastfeeding. All mothers received lamivudine 150 mg, zidovudine 300 mg twice daily and trimethoprim-sulfamethoxazole once daily. All infants received prophylaxis with either zidovudine for 1 week or nevirapine for 6 weeks, plus trimethoprim-sulfamethoxazole from 6 weeks of age to 6 weeks after weaning. Almost all of the infants were exclusively breastfed until 6 months of age and about 73% were partially breastfed until 12 months of age. There was no statistical difference in hospitalizations or adverse events including anemia, neutropenia or deaths among infants in the two groups.[<a class="bibr" href="#LM644.REF.12" rid="LM644.REF.12">12</a>]</p><p>Among 32 breastfed (extent not stated) infants whose mothers were taking efavirenz 600 mg daily as part of a multi-drug treatment for HIV infection, no adverse effects were noted by investigators or reported by mothers at 1, 3 and 6 months of age.[<a class="bibr" href="#LM644.REF.9" rid="LM644.REF.9">9</a>]</p><p>A prospective cohort study in Malawi compared the infants of HIV+ mothers taking efavirenz and tenofovir disoproxil fumarate (n = 260) to infants of mothers who were HIV negative (n = 125). Infants were followed for growth and development for up to 18 months at which time there were 169 mother-infant pairs in the treatment group and 54 in the HIV-negative group. No difference was found in the growth and development of the breastfed infants of treated women compared to the infants of untreated mothers.[<a class="bibr" href="#LM644.REF.13" rid="LM644.REF.13">13</a>]</p><p>An open-label, controlled, multicenter phase 3 trial women who were confirmed HIV-positive were randomized to receive one of 3 regimens: dolutegravir, emtricitabine, and tenofovir alafenamide (n = 208); dolutegravir, emtricitabine, and tenofovir disoproxil fumarate (n = 202); or efavirenz, emtricitabine, and tenofovir disoproxil fumarate (n = 207). The regimens were started at 14 to 28 weeks of pregnancy and continued postpartum. Of the 617 liveborn infants, 99% were breastfeeding at time of last infant HIV test, which was as late as 50 weeks of age. The mean infant duration on the study was 47.6 weeks of age. Infants who had any clinical or laboratory adverse event of grade 3 or higher ranged from 25 to 31%, but was not statistically significant between groups. Dolutegravir-containing regimens resulted in lower rates of virological failure, HIV drug resistance, and infant mortality up to 50 weeks postpartum compared with efavirenz, emtricitabine, and tenofovir disoproxil fumarate.[<a class="bibr" href="#LM644.REF.14" rid="LM644.REF.14">14</a>]</p></div><div id="LM644.Effects_on_Lactation_and_Breastmil"><h3>Effects on Lactation and Breastmilk</h3><p>Gynecomastia has been reported among men and at least one woman receiving efavirenz therapy.[<a class="bibr" href="#LM644.REF.15" rid="LM644.REF.15">15</a>,<a class="bibr" href="#LM644.REF.16" rid="LM644.REF.16">16</a>] Efavirenz appears to be much more likely to cause gynecomastia than other antiretroviral agents. Gynecomastia is unilateral initially, but can progress to bilateral. Spontaneous resolution usually occurred within one year, even with continuation of the regimen. The relevance of these findings to nursing mothers is not known. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.</p></div><div id="LM644.References"><h3>References</h3><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="LM644.REF.1">World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. 2021. <a href="https://www.who.int/publications/i/item/9789240031593" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.who.int/publications<wbr style="display:inline-block"></wbr>​/i/item/9789240031593</a> [<a href="https://pubmed.ncbi.nlm.nih.gov/34370423" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34370423</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="LM644.REF.2">Department of Health and Human Services. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. 2024. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/perinatal-hiv/guidelines-perinatal.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https:<wbr style="display:inline-block"></wbr>​//clinicalinfo<wbr style="display:inline-block"></wbr>​.hiv.gov/sites/default<wbr style="display:inline-block"></wbr>​/files/guidelines/documents<wbr style="display:inline-block"></wbr>​/perinatal-hiv<wbr style="display:inline-block"></wbr>​/guidelines-perinatal.pdf</a></div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="LM644.REF.3">Schneider
|
|
S, Peltier
|
|
A, Gras
|
|
A, et al.
|
|
Efavirenz in human breast milk, mothers', and newborns' plasma.
|
|
J Acquir Immune Defic Syndr
|
|
2008;48:450-4.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/18614925" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18614925</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="LM644.REF.4">Olagunju
|
|
A, Bolaji
|
|
OO, Amara
|
|
A, et al.
|
|
Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.
|
|
J Antimicrob Chemother
|
|
2015;70:555-61.
|
|
[<a href="/pmc/articles/PMC6538536/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6538536</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25326089" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25326089</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="LM644.REF.5">Olagunju
|
|
A, Bolaji
|
|
O, Amara
|
|
A, et al.
|
|
Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: An observational study.
|
|
Clin Infect Dis
|
|
2015;61:453-63.
|
|
[<a href="/pmc/articles/PMC6542686/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6542686</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25882300" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25882300</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="LM644.REF.6">Olagunju
|
|
A, R
|
|
Rajoli, Atoyebi
|
|
S, et al.
|
|
Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding
|
|
AAS Open Research
|
|
2018;1. doi:10.12688/aasopenres.12860.1 [<a href="http://dx.crossref.org/10.12688/aasopenres.12860.1" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">CrossRef</a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="LM644.REF.7">Pan
|
|
X, Rowland Yeo
|
|
K.
|
|
Physiologically based pharmacokinetic modelling to determine the impact of CYP2B6 genotype on efavirenz exposure in children, mothers and breastfeeding infants.
|
|
Clin Pharmacol Ther
|
|
2023;114:182-91.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/37078251" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37078251</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="LM644.REF.8">Palombi
|
|
L, Pirillo
|
|
MF, Marchei
|
|
E, et al.
|
|
Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.
|
|
J Antimicrob Chemother
|
|
2016;71:1027-30.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/26679247" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26679247</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="LM644.REF.9">Oumar
|
|
AA, Bagayoko-Maiga
|
|
K, Bahachimi
|
|
A, et al.
|
|
Efavirenz and lopinavir levels in HIV-infected women and their nursing infants, in Mali.
|
|
J Pharmacol Exp Ther
|
|
2018;366:479-84.
|
|
[<a href="/pmc/articles/PMC11056435/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC11056435</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29986950" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29986950</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="LM644.REF.10">Aebi-Popp
|
|
K, Kahlert
|
|
CR, Crisinel
|
|
PA, et al.
|
|
Transfer of antiretroviral drugs into breastmilk: A prospective study from the Swiss Mother and Child HIV Cohort Study.
|
|
J Antimicrob Chemother
|
|
2022;77:3436-42.
|
|
[<a href="/pmc/articles/PMC9704434/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9704434</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36177836" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36177836</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="LM644.REF.11">Gandhi
|
|
M, Mwesigwa
|
|
J, Aweeka
|
|
F, et al.
|
|
Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding.
|
|
J Acquir Immune Defic Syndr
|
|
2013;63:578-84.
|
|
[<a href="/pmc/articles/PMC3800282/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3800282</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24135775" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24135775</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>12.</dt><dd><div class="bk_ref" id="LM644.REF.12">Cohan
|
|
D, Natureeba
|
|
P, Koss
|
|
CA, et al.
|
|
Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.
|
|
AIDS
|
|
2015;29:183-91.
|
|
[<a href="/pmc/articles/PMC4428759/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4428759</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25426808" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25426808</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>13.</dt><dd><div class="bk_ref" id="LM644.REF.13">Kapito-Tembo
|
|
AP, Bauleni
|
|
A, Wesevich
|
|
A, et al.
|
|
Growth and neurodevelopment outcomes in HIV, tenofovir and efavirenz exposed breastfed infants in PMTCT Option B+ program in Malawi.
|
|
J Acquir Immune Defic Syndr
|
|
2021;86:81-90.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/33027153" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33027153</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>14.</dt><dd><div class="bk_ref" id="LM644.REF.14">Chinula
|
|
L, Ziemba
|
|
L, Brummel
|
|
S, et al.
|
|
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: A multicentre, open-label, randomised, controlled, phase 3 trial.
|
|
Lancet HIV
|
|
2023;10:e363-e374.
|
|
[<a href="/pmc/articles/PMC10280394/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10280394</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37167996" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37167996</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>15.</dt><dd><div class="bk_ref" id="LM644.REF.15">Jover
|
|
F, Cuadrado
|
|
JM, Roig
|
|
P, et al.
|
|
Efavirenz-associated gynecomastia: report of five cases and review of the literature.
|
|
Breast J
|
|
2004;10:244-6.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15125753" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15125753</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>16.</dt><dd><div class="bk_ref" id="LM644.REF.16">Rahim
|
|
S, Ortiz
|
|
O, Maslow
|
|
M, et al.
|
|
A case-control study of gynecomastia in HIV-1-infected patients receiving HAART.
|
|
AIDS Read
|
|
2004;14:23-4, 29-32, 35-40.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/14959701" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14959701</span></a>]</div></dd></dl></dl></div></div><div id="LM644.Substance_Identification"><h2 id="_LM644_Substance_Identification_">Substance Identification</h2><div id="LM644.Substance_Name"><h3>Substance Name</h3><p>Efavirenz</p></div><div id="LM644.CAS_Registry_Number"><h3>CAS Registry Number</h3><p>154635-17-3</p></div><div id="LM644.Drug_Class"><h3>Drug Class</h3><p>Breast Feeding</p><p>Lactation</p><p>Milk, Human</p><p>Anti-Infective Agents</p><p>Antiviral Agents</p><p>Anti-HIV Agents</p><p>Anti-Retroviral Agents</p><p>Reverse Transcriptase Inhibitors</p></div></div><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_top_margin"><p><b>Disclaimer: </b>Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.</p></p></div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK501534_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Revision: <span itemprop="dateModified">July 15, 2024</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a><p class="small"><b>Attribution Statement:</b> LactMed is a registered trademark of the U.S. Department of Health and Human Services.</p></div></div><h3>Publisher</h3><p><a href="https://www.nlm.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Child Health and Human Development</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Efavirenz. [Updated 2024 Jul 15].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/lactmed/LM1194/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/lactmed/efgartigimod_alfa/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|